# A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT02539225** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 191 (actual)

## Conditions studied

- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Placebo
- **DRUG:** S-1
- **DRUG:** Oxaliplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02539225
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-05
- **Primary completion:** 2017-10-25
- **Final completion:** 2021-03-10
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02539225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02539225, "A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02539225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*